Clinical trials: Alzheimer Blood Biomarkers
Alzheimer's Disease
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease.
- Trial name
- NCT00757939
- Testing
- MRI, FDG-PET
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Elderly, Alzheimer Disease
Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spectrum
The goal of this clinical trial is to explore and verify the preventive effects of melatonin on the progression of Alzheimer's disease.
- Conditions
- Elderly, Alzheimer Disease, Melatonin, Cognitive Decline
- Trial name
- NCT06756828
- Testing
- Melatonin, Cognitive behavioral therapy group for insomnia
- Volunteers
- 40 people
- Sponsor
- Saint Vincent's Hospital, Korea
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Mild Cognitive Impairment
Validation of Blood Biomarkers for Alzheimer's Disease
Alzheimer's disease (AD) has gradually become one of the major global public health issues due to its prevalence, which increases with age and life expectancy, and the economic cost of caring for patients whose cognitive decline…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Tauopathies
- Trial name
- ALZAN (NCT05427448)
- Testing
- Measurement of amyloid and pTau blood biomarkers
- Where
- 3 sites in France
- Volunteers
- 342 people
- Sponsor
- University Hospital, Montpellier
Down Syndrome, Down Syndrome (DS)
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome.
- Conditions
- Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Dementia
- Trial name
- LESS-AD (NCT07234695)
- Testing
- Levetiracetam 500mg
- Where
- 5 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Alzheimer's Disease, Safety
Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers
The purpose of the study is to assess the safety, tolerability and blood concentration of AZD3839 following oral administration of single doses in healthy men and women of non-childbearing potential
- Conditions
- Alzheimer's Disease, Safety, Tolerability, Blood Concentration
- Trial name
- NCT01348737
- Testing
- AZD3839
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Mild Cognitive Impairment Due to Alzheimer's Disease, Dementia Due to Alzheimer's Disease (Disorder)
Biomarkers of Cognitive Impairment in Blood Cells
The aim of this study is to identify transcriptomic biomarkers in blood cells to diagnose early cognitive impairment. This would allow preventing the development of severe pathologies, such as Alzheimer Disease.
- Trial name
- COGNIMARK (NCT05582941)
- Testing
- No intervention will be performed.
- Where
- Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of the Balearic Islands
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
Alzheimer's Disease
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
- Trial name
- NCT06043700
- Testing
- No Intervention
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eisai Limited
Cognitive Impairment, Alzheimer Blood Biomarkers
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more…
- Conditions
- Cognitive Impairment, Alzheimer Blood Biomarkers, Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
- Trial name
- NCT07146412
- Testing
- Multimodal Lifestyle Intervention
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- HudsonAlpha Institute for Biotechnology
Cognitive Decline
TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.
The study is based on the hypothesis that the integration of biological, psychological, and social factors, according to the biopsychosocial paradigm, allows for more accurate identification of the different stages of the…
- Trial name
- TRIAD (NCT07399418)
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Mild Dementia, Mild Cognitive Impairment
The Swedish BioFINDER - Primary Care Study
The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics.
- Conditions
- Mild Dementia, Mild Cognitive Impairment, SCD, Alzheimer Disease
- Trial name
- ADetect (NCT06120361)
- Testing
- Plasma APS 2 score, Plasma p-tau217/np-tau217, Plasma p-tau217
- Where
- Sweden
- Volunteers
- 1,200 people
- Sponsor
- Skane University Hospital
Major Depressive Disorder (MDD), Schizophenia Disorder
Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for…
- Conditions
- Major Depressive Disorder (MDD), Schizophenia Disorder, Bipolar 1 Disorder, Alzheimer Disease
- Trial name
- Synapsing-SD (NCT07239843)
- Where
- Spain
- Volunteers
- 1,310 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NPC1-AD (NCT07236190)
- Testing
- natural product combination-1 (NPC1)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Mild Cognitive Impairment (MCI)
A Prospective Cohort Study of Multimodal Biomarkers and Progression From Mild Cognitive Impairment to Dementia
This prospective, longitudinal observational cohort study will examine clinical, cognitive, blood-based, and neuroimaging features across the cognitive continuum.
- Trial name
- NCT07876570
- Testing
- Observational Multimodal Assessment
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer's Disease
A Pilot Study of Inflammatory Markers in Alzheimer's Disease
The purpose of this study is to examine the cerebrospinal fluid (CSF) of patients with Alzheimer's disease for biomarkers of inflammation and their response to the antibiotics doxycycline and rifampin.
- Trial name
- NCT00715858
- Testing
- doxycycline, rifampin
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- McMaster University
Dementia With Lewy Bodies, Alzheimer Disease
DIagnostic Biomarkers and Symptoms in Patients With Alzheimer's Disease and Lewy bodY Dementia
This a study to improve diagnosis of dementia with Lewy bodies with RT-QuIC in different biospecimens.
- Conditions
- Dementia With Lewy Bodies, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- DISPLAY (NCT05768425)
- Testing
- Real-time quaking-induced conversion (RT-QuIC), Cognitive test, Motor examination
- Where
- Denmark
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Danish Dementia Research Centre
Alzheimer Disease
Wearables-and Blood-based Biomarkers-incorporated Modernisation of Circadian Rhythm Disruption Management in People Living With Alzheimer's Dementia: A Stepwise Study From Digital Inclusivity, Digital Therapy, to Digital Phenotyping and Biomarker Exploration
By 2025, Taiwan will become a super-aged society, with the number of Alzheimer's disease patients continuing to rise. However, the vast majority of dementia patients experience "behavioral and psychological symptoms of dementia"…
- Trial name
- NCT07222449
- Testing
- Photobiomodulation
- Where
- Taiwan
- Volunteers
- 162 people
- Sponsor
- China Medical University Hospital
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer Disease
Blood Biomarkers from Internal Jugular Vein for the Diagnosis of Alzheimer's Disease
The goal of this observational study is to explore the diagnostic performance of blood biomarkers from the internal jugular vein for the diagnosis of Alzheimer's disease (AD) in patients with cognitive symptoms or concerns.
- Trial name
- NCT06754254
- Testing
- blood biomarkers from the internal jugular vein
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University